Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Long-Term Deferred Tax (2016)

IGC Pharma has reported Long-Term Deferred Tax over the past 6 years, most recently at $19000.0 for Q4 2016.

  • Quarterly Long-Term Deferred Tax fell 93.76% to $19000.0 in Q4 2016 from the year-ago period, while the trailing twelve-month figure was $19000.0 through Dec 2016, down 93.76% year-over-year, with the annual reading at $356684.0 for FY2016, 11.97% up from the prior year.
  • Long-Term Deferred Tax was $19000.0 for Q4 2016 at IGC Pharma, down from $356619.0 in the prior quarter.
  • Over five years, Long-Term Deferred Tax peaked at $356684.0 in Q1 2016 and troughed at -$14076.0 in Q1 2012.
  • The 5-year median for Long-Term Deferred Tax is $318548.0 (2015), against an average of $287677.3.
  • Year-over-year, Long-Term Deferred Tax soared 2525.8% in 2013 and then plummeted 93.76% in 2016.
  • A 5-year view of Long-Term Deferred Tax shows it stood at -$14076.0 in 2012, then skyrocketed by 2221.59% to $298635.0 in 2013, then increased by 6.54% to $318159.0 in 2014, then dropped by 4.36% to $304272.0 in 2015, then plummeted by 93.76% to $19000.0 in 2016.
  • Per Business Quant, the three most recent readings for IGC's Long-Term Deferred Tax are $19000.0 (Q4 2016), $356619.0 (Q3 2016), and $356334.0 (Q2 2016).